MRI biomarkers in Huntington's disease.
暂无分享,去创建一个
Jeroen van der Grond | M. van Buchem | R. Roos | J. van der Grond | S. V. D. van den Bogaard | E. Dumas | Mark van Buchem | Eve Dumas | Simon van den Bogaard | Raymund Roos
[1] B D Ross,et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases , 1998, Neurology.
[2] G. Pearlson,et al. Frontal lobe volume in patients with Huntington's disease , 1998, Neurology.
[3] Timothy Edward John Behrens,et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease , 2009, NeuroImage.
[4] D. Brooks,et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy , 1994, The Lancet.
[5] E. Vandenbussche,et al. Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation , 2004, Journal of Neurology.
[6] Jeroen van der Grond,et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease , 2012, Human brain mapping.
[7] R. Reilmann,et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease , 2010, Neurology.
[8] Jan Kassubek,et al. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. , 2005, Cerebral cortex.
[9] Jane S. Paulsen,et al. White Matter Volume and Cognitive Dysfunction in Early Huntington's Disease , 2005, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.
[10] J Kassubek,et al. Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[11] G Hör,et al. Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. , 1998, Psychiatry research.
[12] E. Tolosa,et al. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease , 2007, Neurology.
[13] Sarah A. J. Reading,et al. Functional brain changes in presymptomatic Huntington's disease , 2004, Annals of neurology.
[14] Nick C Fox,et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.
[15] R. Roos,et al. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. , 2010, Parkinsonism & related disorders.
[16] Kurt E. Weaver,et al. Longitudinal diffusion tensor imaging in Huntington's Disease , 2009, Experimental Neurology.
[17] A. Dale,et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.
[18] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[19] R. E. Steiner,et al. Clinical NMR imaging of the brain: 140 cases , 1982 .
[20] Anne-Catherine Bachoud-Lévi,et al. Distribution of grey matter atrophy in Huntington’s disease patients: A combined ROI-based and voxel-based morphometric study , 2006, NeuroImage.
[21] A. Ludolph,et al. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[22] C. Hanstock,et al. Is brain lactate increased in Huntington's disease? , 2007, Journal of the Neurological Sciences.
[23] Jane S. Paulsen,et al. fMRI detection of early neural dysfunction in preclinical Huntington's disease , 2007, Journal of the International Neuropsychological Society.
[24] L. Raymond,et al. Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study , 2003, Brain Research Bulletin.
[25] Anusha Sritharan,et al. Increased cortical recruitment in Huntington's disease using a Simon task , 2007, Neuropsychologia.
[26] Sarah A. J. Reading,et al. Functional MRI study of a serial reaction time task in Huntington's disease , 2004, Psychiatry Research: Neuroimaging.
[27] B Fischl,et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.
[28] J. Marinus,et al. Autonomic symptoms in patients and pre‐manifest mutation carriers of Huntington’s disease , 2010, European journal of neurology.
[29] Mario Mascalchi,et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. , 2004, Radiology.
[30] Hans J. Johnson,et al. Cerebral cortex structure in prodromal Huntington disease , 2010, Neurobiology of Disease.
[31] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[32] C D Good,et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. , 2002, Brain : a journal of neurology.
[33] V. Clark,et al. Altered functional MRI responses in Huntington's disease , 2002, Neuroreport.
[34] Jane S. Paulsen,et al. Diffusion Tensor Imaging in Preclinical Huntington’s Disease , 2009, Brain Imaging and Behavior.
[35] Daniel Ecker,et al. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. , 2007, Brain : a journal of neurology.
[36] C. Terrence,et al. Computed tomography for Huntington's disease , 1977, Neuroradiology.
[37] Terry L. Jernigan,et al. Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases , 1991, Biological Psychiatry.
[38] Jane S. Paulsen,et al. CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[39] Stefan Klöppel,et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. , 2008, Brain : a journal of neurology.
[40] N Makris,et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.
[41] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[42] Mark Mühlau,et al. Striatal gray matter loss in Huntington's disease is leftward biased , 2007, Movement disorders : official journal of the Movement Disorder Society.
[43] F. Cendes,et al. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[44] Jane S. Paulsen,et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. , 2004, AJNR. American journal of neuroradiology.
[45] Jane S. Paulsen,et al. Brain Structure in Preclinical Huntington’s Disease , 2006, Biological Psychiatry.
[46] G. Pearlson,et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[47] Jane S. Paulsen,et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.
[48] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[49] B R Rosen,et al. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.
[50] Jane S. Paulsen. Functional imaging in Huntington's disease , 2009, Experimental Neurology.
[51] Wilhelm Gaus,et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.
[52] R. Barker,et al. The current clinical management of Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[53] R. Roos,et al. Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease , 2008, Journal of Neurology.
[54] Frederik Maes,et al. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease , 2009, Journal of Neurology.
[55] F Cendes,et al. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[56] Nick C. Fox,et al. Rate and acceleration of whole‐brain atrophy in premanifest and early Huntington's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[57] Nick C Fox,et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease , 2009, Journal of Neurology.
[58] J. Brandt,et al. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. , 1995, Journal of clinical and experimental neuropsychology.
[59] Daniel Ecker,et al. Cortical dysfunction in patients with Huntington's disease during working memory performance , 2009, Human brain mapping.
[60] J. Caboche,et al. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments , 2008, Current opinion in neurology.
[61] P. Sundgren,et al. Magnetic resonance spectroscopy. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[62] Jane S. Paulsen,et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[63] Massimo Filippi,et al. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve , 2007, Neurotherapeutics.
[64] N. Georgiou-Karistianis,et al. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle? , 2009, Experimental Neurology.
[65] Jane S. Paulsen,et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease , 2010, Brain Research Bulletin.
[66] M Filippi,et al. Regional Distribution and Clinical Correlates of White Matter Structural Damage in Huntington Disease: A Tract-Based Spatial Statistics Study , 2010, American Journal of Neuroradiology.
[67] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[68] E. Tolosa,et al. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. , 2009, Parkinsonism & related disorders.
[69] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[70] Nick C Fox,et al. Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study , 2010, American Journal of Neuroradiology.
[71] A. Blamire,et al. High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study , 2005, Neurology.
[72] R. V. D. Mast,et al. Psychopathology in verified Huntington's disease gene carriers. , 2007, The Journal of neuropsychiatry and clinical neurosciences.
[73] Sarah A. J. Reading,et al. Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study , 2005, Psychiatry Research: Neuroimaging.
[74] Nick C Fox,et al. Increased rate of whole-brain atrophy over 6 months in early Huntington disease , 2006, Neurology.
[75] J. Bradshaw,et al. Functional connectivity of the prefrontal cortex in Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[76] Josephine Barnes,et al. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[77] R. Roos,et al. 1H magnetic resonance spectroscopy in preclinical Huntington disease , 2007, Brain Research.
[78] Sarah J Tabrizi,et al. Huntington’s disease , 2010, BMJ : British Medical Journal.
[79] R. Prost,et al. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease , 2005, Brain Research.
[80] G. Pearlson,et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.
[81] Nick C Fox,et al. Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[82] C. Schönfeldt-Lecuona,et al. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease , 2008, Experimental Neurology.
[83] F. Cendes,et al. Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy , 2007, Movement disorders : official journal of the Movement Disorder Society.
[84] J. Willey,et al. PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.
[85] Elizabeth H. Aylward,et al. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.
[86] S. Folstein,et al. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study , 1992, Neuroradiology.
[87] Gordon J. Gilbert. WEIGHT LOSS IN HUNTINGTON DISEASE INCREASES WITH HIGHER CAG REPEAT NUMBER , 2009 .
[88] J. D. de Yébenes,et al. Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.
[89] John L Bradshaw,et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[90] J. Brandt,et al. When does Huntington's disease begin? , 1998, Journal of the International Neuropsychological Society.
[91] H. Diana Rosas,et al. Neuroprotection for Huntington’s disease: Ready, set, slow , 2008, Neurotherapeutics.
[92] A. Aron,et al. Contrasting gray and white matter changes in preclinical Huntington disease , 2010, Neurology.
[93] S. Folstein,et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.
[94] M. Battaglini,et al. Magnetization Transfer MR Imaging Demonstrates Degeneration of the Subcortical and Cortical Gray Matter in Huntington Disease , 2010, American Journal of Neuroradiology.
[95] J. Brandt,et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. , 1999, Brain : a journal of neurology.
[96] Jeroen van der Grond,et al. Magnetization transfer imaging in ‘premanifest’ Huntington’s disease , 2009, Journal of Neurology.
[97] Jan Kassubek,et al. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study , 2005, Journal of the Neurological Sciences.
[98] R. Reilmann,et al. Creatine supplementation lowers brain glutamate levels in Huntington’s disease , 2005, Journal of Neurology.
[99] B. Rosen,et al. Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.
[100] C. Clarke,et al. No change in striatal glutamate in Huntington's disease measured by proton magnetic resonance spectroscopy. , 1998, Parkinsonism & related disorders.
[101] Peng Yu,et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical “disconnection” , 2010, NeuroImage.
[102] Nick C Fox,et al. Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease , 2010, American Journal of Neuroradiology.
[103] R. C. Wolf,et al. Funktionelle Bildgebung kognitiver Prozesse bei M.-Huntington-Patienten und präsymptomatischen Mutationsträgern , 2008, Der Nervenarzt.
[104] Chris Frost,et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.
[105] Jane S. Paulsen,et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.
[106] J. Ashburner,et al. Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[107] Jeroen van der Grond,et al. Early atrophy of pallidum and accumbens nucleus in Huntington’s disease , 2010, Journal of Neurology.
[108] J. Brandt,et al. Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.
[109] Klaus Seppi,et al. Diffusion‐weighted imaging in Huntington's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[110] Bruce Fischl,et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.
[111] M. MacDonald,et al. CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.
[112] D. Brooks,et al. Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? , 1996, Movement disorders : official journal of the Movement Disorder Society.
[113] B R Rosen,et al. 1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.
[114] David S Tuch,et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.
[115] Jane S. Paulsen,et al. Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.
[116] G. Barker,et al. Proton MRS in Huntington's disease , 1994, The Lancet.